Physician profile
Dane H Slentz
NPI 1639580327
$126,633.32
in general payments reported to CMS, 2019-2025
19 companies · $40K in 2025
The $40K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2021: $279 · 2022: $11K · 2023: $37K · 2024: $38K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Honoraria: $31K · Travel and Lodging: $12K · Consulting Fee: $8,500 · Food and Beverage: $7,775 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $55,143.75 |
| Honoraria | $31,093.75 |
| Travel and Lodging | $12,238.06 |
| Consulting Fee | $8,500.00 |
| Food and Beverage | $7,774.92 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75,229.14 | 2024-2025 | Tepezza, Uplizna |
| Horizon Therapeutics Plc | $48,014.57 | 2021-2023 | Tepezza, Uplizna |
| Ani Pharmaceuticals, INC. | $706.68 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Biotissue Holdings INC. | $627.66 | 2021-2025 | |
| Oyster Point Pharma, INC. | $278.89 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Genentech USA, INC. | $258.54 | 2019-2024 | Vabysmo |
| Bausch & Lomb Americas INC. | $221.67 | 2024-2025 | Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $210.12 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $201.87 | 2019-2025 | Rocklatan, Rhopressa |
| Sight Sciences, INC. | $180.87 | 2023-2024 | Tearcare System |
| Sun Pharmaceutical Industries INC. | $156.15 | 2022-2025 | Cequa |
| Rxsight INC | $149.63 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Abbvie INC. | $130.95 | 2025 | |
| Mallinckrodt Hospital Products INC. | $104.97 | 2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $66.33 | 2024-2025 | Eylea Hd |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.44 | 2024 | Izervay |
| Glaukos Corporation | $23.86 | 2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Alimera Sciences, INC. | $19.35 | 2024 | Iluvien, Yutiq |
| Thea Pharma INC. | $18.63 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dane Slentz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.